2021-08-001 - NeurAntigenv2 - A Human Neural Platform for Assaying Antigen- Antibody Interactions for Autoimmune Encephalitis
Contacts
LT
Acronim & Gínjol codes
NeurAntigenv2
2021-08-001
Main technology offer
Procedure to identify the presence of autoantibodies against neural antigens using human induced pluripotent stem cell (hiPSC)-derived neural cellsThe proposed diagnostic product is the first one using human stem cell derived neural cells.
Ownership
L'Hospitalet de Llobregat, Spain
2004
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)
Public Partners
Readiness Level
3-4 Experimental PoC /
5 Prototype /
6-7 MVP /
8 Industrialization /
9 Commercialization
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
Impact: ESG & SDG Goals
The in vitro diganostic will require low volumes of medium to test the Ab & the development done on public institution will ensure the public governance
Be able to diagnose on early stages and even to diagnose as positive patients previously diagnosed as negative
Market Data
The problem: Autoimmune encephalitis (AiE) is a severe brain inflammatory disorder produced by an immune attack to neurons. Detection of neuronal antibodies in patient serum and cerebrospinal fluid, is key to establish a definitive diagnosis. The Solution: To solve this we developed NeurAntigen (NA), with substantial advantages: based on neurons derived from human induced pluripotent stem cells, expresses all potential neuronal autoantigens, includes nonneural cells as control (easier interpretation of results). We propose NeurAntigen as first diagnostic step to demonstrate or rule out the presence of neuronal ab in patients with suspected AiE. We aim to validate its diagnostic accuracy, effectiveness in a real-world environment, consolidate the IPR strategy and develop a solid regulatory and commercialization plan. NeurAntigen reduces the diagnostic delay for AiE and avoids the performance of unnecessary tests for patients with negative results, provides increased sensitivity and specificity, facilitating a prompt diagnosis, treatment and impacting on clinical practice, improving the use of resources.
0
0
0
The business model is intended to be a co-development project or license the technology to a pharma that could be itnerested in
The global Encephalitis Treatment Market is projected to expand at a moderate CAGR of 5.4% from 2023 to 2033. The introduction of our method as a screening tool for patients with AiE and related diseases will be an opportunity for the diagnostic market in the autoimmune disease field, expected to reach 5B USD in 2025, growing with CAGR of 4.1% according to a study by Grand View Research.
epidemiological studies suggest that AE is possibly as common as infectious encephalitis with an estimated prevalence rate of 13.7/100 000. The rapidly advancing knowledge of new antibodies and their associated syndromes has created a new and growing field
Funding
The project is looking for fundings for its validation and future translability to clinical practice by out-liscencing the technology
Funding for validation and licensing of the technology to a pharma of interest
Patent application. Validation of the results in international hospitals.
Technology Status
We want to validate our in vitro asset to confirm the diagnose of the autoimmune encephalitis not only by the detection of antibodies but also buy its punctuated pattern. Additionally, this new diagnostic will be able to identify patients that were not able to be diagnose by previous test
Narrow market and treatment options once diagnosed
Once the patent will be granted, the technology will be presented in different congresses and to different pharmas of interest to liscence the technology
EP23383041.3 priority date: 10/10/2023 PCT filed (PCT/EP2024/078537) Patent published: date 17/04/2025
under development
Additional information
Our proposed diagnostic platform presents additional advantages in comparison with currently existing diagnostic methods for AE and it is